Metraipolis › archive › dc_8da01403e882
Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma — Europe PMC PMID:42133639
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42133639
- DOI
- 10.1371/journal.pone.0349044
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-07T21:46:04.033Z
- SHA-256 of the archived text
33084fc187dc69d73c5214bbe1873ac5db0c60f4f6dbaaa01e1a9be825c55060- Stable URL of this page
https://metraipolis.com/documento/dc_8da01403e882
How to cite
Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma — Europe PMC PMID:42133639 — Europe PMC (en), https://europepmc.org/article/MED/42133639 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8da01403e882 (Metraipolis archive dc_8da01403e882, sha256 33084fc187dc69d73c5214bbe1873ac5db0c60f4f6dbaaa01e1a9be825c55060)
BibTeX
@misc{dc8da01403e882,
title = {Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma — Europe PMC PMID:42133639},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42133639},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8da01403e882; sha256 33084fc187dc69d73c5214bbe1873ac5db0c60f4f6dbaaa01e1a9be825c55060},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42133639. Agents can read the archived copy with the MCP tool read_document.